 About the EyeGate® II Delivery SystemEyeGate Pharma's transcleral (transmitted across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was designed by ophthalmologists for ophthalmologists based on over ten years of development and a strong body of scientific and proof-of-concept data at the University of Miami and later at the Hotel-Dieu Hospital in Paris. EyeGate Pharma has optimized these developments into a commercially viable technology platform and is ready to take medicines in combination with the delivery system through the regulatory approval process in both the U.S. and Europe and onto global commercialization. |
|
 |
